Search

Your search keyword '"Sharpe, Michaela E."' showing total 11 results
Start Over Author "Sharpe, Michaela E."
11 results on '"Sharpe, Michaela E."'

3. Polar localization of the MinD protein of Bacillus subtilis and its role in selection of the mid-cell division site

Author

Marston, Adele L., Thomaides, Helena B., Edwards, David H., Sharpe, Michaela E., and Errington, Jeffery

Subjects
Bacteria -- Research, Cell division -- Research, Cytokinesis -- Research, Proteins -- Research, Biological sciences
Abstract

Rod-shaped bacteria divide cells by forming a ring of the protein FtsZ at mid-cell, and the MinCD protein is sequestered at cell poles to prevent further division. The Bacillus subtilis DivIVA protein controls how the MinCD behaves. Locating MinCD at cell poles also releases the next sites for division, yet this mechanism is entirely different from this action of the MinE protein, although both systems use MinCD as a division inhibitor.

Published
1998

4. Bacillus subtilis cell cycle as studied by fluoresence microscopy: constancy of cell length at initiation of DNA replication and evidence for active nucleoid partitioning

Author

Sharpe, Michaela E., Hauser, Philippe M., Sharpe, Robert G., and Errington, Jeffery

Subjects
Bacillus subtilis -- Research, Cell cycle -- Analysis, Biological sciences
Abstract

Research was conducted to characterize the cell cycle of Bacillus subtilis at varying growth rates using fluorescence microscopic techniques. Results show that chromosome replication for B. subtilis as well as cell mass at initiation of DNA replication were similar to Escherichia coli. However, the bacteria differs with E. coli with regard to cell cycle and the relative variability of period between termination of DNA replication and septation.

Published
1998

8. Concise Review : Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies

Author

Heslop, James A., Hammond, Thomas G., Santeramo, Ilaria, Piella, Agnes Tort, Hopp, Isabel, Zhou, Jing, Baty, Roua, Graziano, Enrique I., Marco, Bernabe Proto, Caron, Alexis, Sköld, Patrik, Andrews, Peter W., Baxter, Melissa A., Hay, David C., Hamdam, Junnat, Sharpe, Michaela E., Patel, Sara, Jones, David R., Reinhardt, Jens, Danen, Erik H. J., Ben-David, Uri, Stacey, Glyn, Bjorquist, Petter, Piner, Jacqueline, Mills, John, Rowe, Cliff, Pellegrini, Giovanni, Sethu, Swaminathan, Antoine, Daniel J., Cross, Michael J., Murray, Patricia, Williams, Dominic P., Kitteringham, Neil R., Goldring, Chris E. P., Park, B. Kevin, Heslop, James A., Hammond, Thomas G., Santeramo, Ilaria, Piella, Agnes Tort, Hopp, Isabel, Zhou, Jing, Baty, Roua, Graziano, Enrique I., Marco, Bernabe Proto, Caron, Alexis, Sköld, Patrik, Andrews, Peter W., Baxter, Melissa A., Hay, David C., Hamdam, Junnat, Sharpe, Michaela E., Patel, Sara, Jones, David R., Reinhardt, Jens, Danen, Erik H. J., Ben-David, Uri, Stacey, Glyn, Bjorquist, Petter, Piner, Jacqueline, Mills, John, Rowe, Cliff, Pellegrini, Giovanni, Sethu, Swaminathan, Antoine, Daniel J., Cross, Michael J., Murray, Patricia, Williams, Dominic P., Kitteringham, Neil R., Goldring, Chris E. P., and Park, B. Kevin

Abstract

The field of stem cell therapeutics is moving ever closer to widespread application in the clinic. However, despite the undoubted potential held by these therapies, the balance between risk and benefit remains difficult to predict. As in any new field, a lack of previous application in man and gaps in the underlying science mean that regulators and investigators continue to look for a balance between minimizing potential risk and ensuring therapies are not needlessly kept from patients. Here, we attempt to identify the important safety issues, assessing the current advances in scientific knowledge and how they may translate to clinical therapeutic strategies in the identification and management of these risks. We also investigate the tools and techniques currently available to researchers during preclinical and clinical development of stem cell products, their utility and limitations, and how these tools may be strategically used in the development of these therapies. We conclude that ensuring safety through cutting-edge science and robust assays, coupled with regular and open discussions between regulators and academic/industrial investigators, is likely to prove the most fruitful route to ensuring the safest possible development of new products.

Published
2015
Full Text
View/download PDF

9. Concise Review: Workshop Review: Understanding and Assessing the Risks of Stem Cell-Based Therapies

Author

Heslop, James A., primary, Hammond, Thomas G., additional, Santeramo, Ilaria, additional, Tort Piella, Agnès, additional, Hopp, Isabel, additional, Zhou, Jing, additional, Baty, Roua, additional, Graziano, Enrique I., additional, Proto Marco, Bernabé, additional, Caron, Alexis, additional, Sköld, Patrik, additional, Andrews, Peter W., additional, Baxter, Melissa A., additional, Hay, David C., additional, Hamdam, Junnat, additional, Sharpe, Michaela E., additional, Patel, Sara, additional, Jones, David R., additional, Reinhardt, Jens, additional, Danen, Erik H.J., additional, Ben-David, Uri, additional, Stacey, Glyn, additional, Björquist, Petter, additional, Piner, Jacqueline, additional, Mills, John, additional, Rowe, Cliff, additional, Pellegrini, Giovanni, additional, Sethu, Swaminathan, additional, Antoine, Daniel J., additional, Cross, Michael J., additional, Murray, Patricia, additional, Williams, Dominic P., additional, Kitteringham, Neil R., additional, Goldring, Chris E.P., additional, and Park, B. Kevin, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results